Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer
- Interventions
- Drug: Abiraterone+SHR3162
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04108247
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04108234
- Locations
- 🇨🇳
Beijing AnDing hospital affiliated to Capital Medical University, Beijing, Beijing, China
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04108676
- Locations
- 🇨🇳
The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
- Conditions
- Prostate CancerCastration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04102124
- Locations
- 🇨🇳
Ye Dingwei, Shanghai, China
A Study of SHR4010 in Patients With Hemodialysis
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04099927
- Locations
- 🇨🇳
Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu, China
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
- Conditions
- Gout
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 594
- Registration Number
- NCT04052932
- Locations
- 🇨🇳
RenJi Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT04041011
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of SHR-1501 in Patients With Advanced Tumors
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04025957
- Locations
- 🇨🇳
Cancer hospital, Chinese academy of medical sciences, Beijing, China
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
- Conditions
- Solid Tumor
- Interventions
- Drug: [14C]-Fluzoparib
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04013048
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04011124
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China